# Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC

> **NCT03226236** · PHASE2 · WITHDRAWN · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS**

## Conditions studied

- Carcinoma, Renal Cell
- Vaccination
- Secondary

## Interventions

- **RADIATION:** boost radiotherapy (XRT)
- **BIOLOGICAL:** Autologous DC vaccine
- **DRUG:** High-Dose IL-2

## Key facts

- **NCT ID:** NCT03226236
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-03
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients enrolled due to change in standard practice
- **Last updated:** 2018-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226236, "Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03226236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*